Brendan Teehan - 29 Apr 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, Head of Commercial
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
29 Apr 2023
Net transactions value
-$11,607
Form type
4
Filing time
02 May 2023, 19:04:58 UTC
Previous filing
07 Apr 2023
Next filing
03 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +1,567 +19% $0.000000 10,035 29 Apr 2023 Direct
transaction ACAD Common Stock Sale $11,607 -548 -5.5% $21.18 9,487 01 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1,567 -100% $0.000000* 0 29 Apr 2023 Common Stock 1,567 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023.